Age Related Macular Degeneration

Causes

AMD develops from a combination of aging, genetics, and lifestyle-related factors that gradually compromise the macula’s cellular structure and blood supply.

• Age — the single greatest risk factor; the risk of AMD increases substantially after age 50, as retinal cells naturally lose regenerative capacity over time.
• Genetics — variations in certain genes (including those involved in the complement immune pathway) are strongly associated with AMD risk, and a family history of the condition roughly doubles an individual’s own risk.
• Smoking — one of the most significant modifiable risk factors; smokers are up to four times more likely to develop AMD than non-smokers, due to oxidative damage and reduced blood flow to the retina.
• Cardiovascular factors — high blood pressure, high cholesterol, and atherosclerosis can restrict the blood supply to the choroid and retina, accelerating macular damage.
• Diet and nutrition — low intake of antioxidants such as lutein, zeaxanthin, and omega-3 fatty acids is associated with a higher risk of progression.
• Prolonged UV/blue light exposure — cumulative light exposure over a lifetime is believed to contribute to oxidative stress in retinal pigment epithelial cells.
• Obesity and inactivity — associated with a higher likelihood of progression from early to advanced AMD.

Because dry and wet AMD arise through somewhat different mechanisms — gradual atrophy versus abnormal vessel growth — the underlying cause has some bearing on how a regenerative treatment approach is tailored for each patient. Learn more about the science behind cellular repair in the retina in our Mechanism section below.

Symptoms

AMD typically progresses slowly, especially in its early dry form, which is why regular eye exams are important even before symptoms become noticeable. Common signs include:

• Blurring or haziness in the center of vision
• Difficulty reading fine print or recognizing faces at a normal distance
• Straight lines appearing wavy, bent, or distorted (a hallmark sign known as metamorphopsia)
• A dark, empty, or blurry patch appearing in the middle of the visual field
• Reduced brightness or intensity of colors
• Needing brighter light to read or perform close-up tasks
• Slower adjustment when moving from bright to dim environments
• Difficulty recognizing faces in dim lighting

Because peripheral vision is typically preserved, many people don’t realize how much central vision they’ve lost until it interferes with a specific task like reading or driving. If you notice sudden distortion, a new blind spot, or rapid worsening of central vision, prompt evaluation is important — wet AMD in particular can progress within days to weeks. See the Diagnosis section for how these symptoms are formally assessed.

Diagnosis

Because AMD affects only the central retina, diagnosis relies on a combination of structural imaging and functional vision testing to determine both the type and stage of the disease.

• Comprehensive dilated eye exam — allows the ophthalmologist to directly visualize the macula and detect drusen deposits, pigment changes, or areas of atrophy.
• Optical Coherence Tomography (OCT) — a non-invasive imaging technique that produces detailed cross-sectional images of the retina, helping detect fluid, swelling, or thinning of the macular layers.
• Fluorescein or Indocyanine Green Angiography — a dye is injected into the bloodstream and photographed as it passes through retinal blood vessels, helping identify abnormal or leaking vessels characteristic of wet AMD.
• Amsler Grid Test — a simple grid-pattern test that helps detect early distortion or missing areas in central vision, often used for self-monitoring between clinic visits.
• Visual Acuity Testing — measures how clearly a person can see at various distances, providing a baseline to track progression or improvement over time.

At Viezec, these evaluations are performed under the supervision of retina specialists and ophthalmologists to accurately stage the condition before any regenerative therapy is considered. This staging also determines eligibility, expected treatment cost, and realistic goals for the therapy.

How Stem Cell Therapy for AMD Works

Stem cell-based approaches for AMD are being researched primarily for their potential to support or replace the retinal pigment epithelium (RPE) — a critical layer of cells that nourishes and maintains photoreceptors. When RPE cells degenerate, photoreceptors above them lose support and eventually die, which is the central mechanism behind vision loss in AMD.

Cells such as mesenchymal stem cells (MSCs), and in some research settings RPE-like cells derived from pluripotent stem cells, are studied for their ability to:

• Support and potentially replace damaged RPE cells
• Secrete neurotrophic and anti-inflammatory factors that help protect surviving photoreceptors
• Improve local microcirculation and nutrient supply to the retina
• Modulate the chronic low-grade inflammation associated with AMD progression

Treatment Pathway

1. Comprehensive evaluation — retinal imaging, visual function tests, and general health screening determine candidacy (see Diagnosis).
2. Stem cell sourcing — selection of an appropriate autologous or allogeneic cell source, with HLA compatibility testing performed when donor cells are used.
3. Laboratory processing — cells are cultured, expanded, and where applicable, differentiated under GMP-certified laboratory conditions with strict quality control (see Delivery Method).
4. Administration — cells are delivered via the route best suited to the individual’s retinal condition, most commonly subretinal, intravitreal, or intravenous.
5. Post-treatment monitoring — structured follow-up using OCT imaging and visual acuity testing to track any changes over time.

What to Expect

Reported outcomes vary widely and depend heavily on the stage of AMD, patient age, and how much retinal tissue remains viable at the time of treatment. Some patients report stabilization of vision loss or modest improvements in contrast sensitivity and reading ability within three to six months; complete reversal of vision loss, particularly in advanced disease, is uncommon. This remains an investigational, evolving area of regenerative medicine and is intended to complement — not replace — standard ophthalmic care.

Delivery Method

The method used to deliver stem cells to the retina is one of the most important technical aspects of AMD treatment, since the goal is to place cells as close as possible to the site of degeneration while minimizing risk to surrounding healthy tissue.

• Subretinal injection — cells are delivered directly beneath the retina, close to the site of RPE damage; typically used when localized cell replacement is the goal.
• Intravitreal injection — cells or cell-derived factors are injected into the vitreous cavity of the eye, allowing diffusion toward the retina; a less invasive option compared to subretinal delivery.
• Intravenous (IV) infusion — used in some protocols to deliver cells systemically, allowing broader anti-inflammatory and trophic support.

Every procedure is carried out in GMP- and ISO-certified laboratory environments, with strict sterility and infection-control standards, and no fetal or embryonic stem cells are used in any protocol. To understand these delivery routes in greater technical depth, visit our page on Stem Cell Delivery Methods.

Improvements

Based on structured patient follow-ups, reported improvements associated with stem cell–based approaches to AMD include:

• Central vision clarity — some patients report an improved ability to read larger print or make out fine detail.
• Contrast sensitivity — improved ability to distinguish objects from their background, particularly helpful in low-light settings.
• Color perception — modest improvements in color brightness and intensity have been reported by some patients.
• Stabilized disease progression — perhaps the most consistently observed benefit, with follow-up OCT imaging showing slowed rates of further macular thinning in a subset of patients.

It’s important to understand that outcomes are individual and cannot be guaranteed — they depend on disease stage, age, and how much viable retinal tissue remains at the time of treatment. For related retinal complications sometimes seen alongside AMD, see our pages on Retinopathy and Optic Neuropathy.

Mechanism

Stem cells are studied for their potential to act less as direct cell replacements and more as biological support agents for the retina — secreting factors that protect and stabilize surviving tissue while, in some research contexts, contributing to structural regeneration of the RPE layer. Key mechanisms under investigation include:

• RPE support and regeneration — differentiation into RPE-like cells that may help re-establish the barrier and nourishing function this layer normally provides.
• Neuroprotection — release of neurotrophic factors that help protect photoreceptors from further degeneration.
• Anti-inflammatory modulation — reduction of the chronic low-grade inflammation implicated in AMD progression, particularly relevant to the complement-driven pathway seen in many AMD patients.
• Antioxidant support — secretion of factors that may help counter oxidative stress, one of the key drivers of retinal pigment cell damage over time.
• Improved microcirculation — supporting blood flow to the choroid and retina, which can be compromised in both dry and wet AMD.

This multi-pronged mechanism is why MSC-based research spans both dry and wet AMD, even though the two forms differ in their underlying pathology. Learn more about the broader biological principles behind these mechanisms on our page about How Stem Cell Therapy Works.

Our Promise

Regenerative medicine for eye disease is a rapidly evolving field, and we believe patients deserve clarity, safety, and realistic expectations at every stage. Our commitments include:

• Recommending treatment only after a thorough, specialist-led ophthalmological evaluation.
• Maintaining transparent communication about what stem cell therapy can and cannot be expected to achieve.
• Upholding strict GMP, ISO, and quality-control standards throughout sourcing, processing, and administration.
• Ensuring no fetal or embryonic stem cells are used in any protocol.
• Providing continuous support and monitoring throughout the patient’s treatment journey.

To understand why many international patients choose India for regenerative eye care — including cost, expertise, and infrastructure — visit our page on Why Stem Cell Therapy in India.

Treatment Results

Patients undergoing stem cell therapy for AMD are monitored through scheduled OCT imaging, fundus examination, and visual acuity testing to objectively track any change over time. Commonly reported outcomes include improved central vision clarity, better color perception, and greater day-to-day visual comfort — with many patients noting functional gains within six to twelve months of treatment.

As with any investigational regenerative approach, outcomes are not guaranteed and vary based on disease stage, age, and individual biological response. Viezec does not claim a complete cure for AMD; rather, the goal is to slow progression and, where possible, support meaningful functional improvement. Learn more about the science underpinning these results on our page about How Stem Cell Therapy Works.

Testimonials

William T. – Melbourne, Australia – February 2020 – ⭐⭐⭐⭐☆
“I had trouble reading even large text due to AMD. After Viezec’s stem cell therapy, my central vision improved, and I can now enjoy books again.”

Amina H. – Nairobi, Kenya – July 2020 – ⭐⭐⭐⭐⭐
“My mother’s AMD was progressing quickly. Post-treatment at Viezec, her vision stabilized, and she recognizes faces more clearly.”

Karl S. – Berlin, Germany – January 2021 – ⭐⭐⭐⭐☆
“AMD left me with blurred central vision. After stem cell therapy, my eyesight became sharper, and daily activities feel easier.”

Fatou D. – Dakar, Senegal – September 2021 – ⭐⭐⭐⭐⭐
“My father was unable to drive due to vision loss. Following Viezec’s therapy, his vision stabilized, and he feels more confident outdoors.”

Miguel R. – São Paulo, Brazil – March 2022 – ⭐⭐⭐⭐☆
“I struggled with dark patches in my sight. Viezec’s stem cell treatment improved my visual clarity and reduced blind spots.”

Helena K. – Warsaw, Poland – October 2022 – ⭐⭐⭐⭐⭐
“AMD was taking away my independence. After Viezec’s therapy, my vision stopped worsening, and I regained hope for the future.”

Omar F. – Muscat, Oman – April 2023 – ⭐⭐⭐⭐☆
“Reading and writing were difficult due to macular degeneration. Post stem cell treatment, my focus improved, and I can enjoy daily tasks again.”

Maria C. – Lisbon, Portugal – November 2023 – ⭐⭐⭐⭐⭐
“My mother’s vision improved after treatment at Viezec. She can now see TV clearly and enjoys painting again.”

George L. – Toronto, Canada – January 2024 – ⭐⭐⭐⭐☆
“Central vision loss made me dependent on others. After Viezec’s stem cell therapy, I regained confidence in managing daily life.”

Yasmin A. – Istanbul, Turkey – June 2025 – ⭐⭐⭐⭐⭐
“I feared total blindness due to AMD. Viezec’s therapy improved my vision stability, and I can still enjoy reading and family gatherings.”

Treatment Disclaimer

The content provided here on Age-Related Macular Degeneration is intended for informational and educational purposes only and should not be considered a substitute for professional medical consultation, diagnosis, or treatment.

• Every patient’s condition, disease stage, and response to therapy are unique; general descriptions here may not directly apply to your individual case.
• Viezec facilitates access to medically guided, investigational regenerative programs based on current research and ophthalmological standards but cannot guarantee specific visual outcomes.
• No fetal or embryonic stem cells are used in any of our treatment protocols.
• If you experience sudden worsening of vision, distortion, or a new blind spot, seek immediate evaluation from an ophthalmologist rather than waiting for a scheduled appointment.

For a personalized recommendation, please request a professional evaluation through our contact page. Our medical team performs a comprehensive review of your diagnostic history before suggesting any treatment approach.